Treatment decisions for elderly GBM patients should take MGMT status into account, and it is reasonable to withhold TMZ from those with newly diagnosed GBM lacking MGMT promoter methylation in clinical trial settings [29]. The gene discussed is MGMT; the disease is glioblastoma.